Abstract
This chapter will present a pathophysiologic paradigm that occurs in solid tumors that is characterized by a self-propagating cycle of abnormally regulated angiogenesis, instability in perfusion, and hypoxia. Interactions between tumor and endothelial cells occur during tumor growth and in response to therapy. These interactions are of central importance in establishing codependence that contributes to promotion of cell survival, treatment resistance, enhanced invasion, and metastasis. Results indicate that concurrent targeting of both tumor and endothelial cells may be of central importance in improving treatment responses to both radiation and chemotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Kraus RM, Stallings HW III, Yeager RC, Gavin, TP. Circulating plasma VEGF response to exercise in sedentary and endurance-trained men. J Appl Physiol 2004; 96:1445–1450.
Wilkinson-Berka JL. Vasoactive factors and diabetic retinopathy: vascular endothelial growth factor, cycoloxygenase-2 and nitric oxide. Curr Pharm Des 2004; 10:3331–3348.
Folkman J, Hanahan D. Switch to the angiogenic phenotype during tumorigenesis. Princess Takamatsu Symp 1991; 22:339–347.
Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3:721–732.
Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res 1995; 55:4575–580.
Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423–27.
Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1 alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21:3995–1004.
Zundel W, Schindler C, Haas-Kogan D, et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 2000; 14:391–396.
Arany Z, Huang LE, Eckner R, et al. An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci U S A 1996; 93:12,969–12,973.
Zhou J, Fandrey J, Schumann J, Tiegs G, Brune B. NO and TNF-alpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am J Physiol 2003; 284:C439–C446.
Yang ZZ, Zhang AY, Yi FX, Li PL, Zou AP. Redox regulation of HIF-1 alpha levels and HO-1 expression in renal medullary interstitial cells. Am J Physiol Renal Physiol 2003; 284: F1207–F1215.
Kuppusamy P, Li H, Ilangovan G, et al. Noninvasive imaging of tumorredox status and its modification by tissue glutathione levels. Cancer Res 2002; 62:307–312.
Kimura H, Braun RD, Ong ET, et al. Fluctuations in red cell flux in tumor micro vessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res 1996; 56:5522–5528.
Braun RD, Lanzen JL, Dewhirst MW. Fourier analysis of fluctuations of oxygen tension and blood flow in R3230Ac tumors and muscle in rats. Am J Physiol 1999; 277(2 Pt 2):H551–H568.
Patan S, Munn LL, Jain RK. Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996; 51:260–272.
Burri PH, Hlushchuk R, Djonov V. Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. Dev Dyn 2004; 231:474-488.
Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS 1997; 79:1–8.
Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 18:5356–5362.
Dewhirst MW. Concepts of oxygen transport at the microcirculatory level. Semin Radiat Onco, 1998; 8:143–150.
Gulledge CJ, Dewhirst MW. Tumor oxygenation: amatterof supply and demand. Anticancer Res 1996; 16:741–749.
Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002; 99:11,399–11,404.
Passalidou E, Trivella M, Singh N, et al. Vascular phenotype in angiogenic and non-angiogenic lung non-small cell carcinomas. Br J Cancer 2002; 86:244–249.
Stessels F, Van den Eynden G, Van der Auwera I, et al. Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. Br J Cancer 2004; 90:1429–1436.
Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61:6624–6628.
Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002; 99:11,393–11,398.
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25:581–611.
Peoch M, Farion R, Hiou A, Le Bas JF, Pasquier B, Remy, C. Immunohistochemical study of VEGF, angiopoietin 2 and their receptors in the neovascularization following microinjection of C6 glioma cells into rat brain. Anticancer Res 2002; 22:2147–2151.
Kimura H, Esumi H. Reciprocal regulation between nitric oxide and vascular endothelial growth factor in angiogenesis. Acta Biochim Pol 2003; 50:49–59.
Brekken RA, Thorpe PE. VEGF-VEGF receptor complexes as markers of tumor vascular endothelium. J Control Release 2001; 74:173–181.
Haroon ZA, Lai TS, Hettasch JM, Lindberg RA, Dewhirst MW, Greenberg CS. Tissue transglutaminase is expressed as a host response to tumor invasion and inhibits tumor growth. Lab Invest 1999; 79:1679–1686.
Hettasch JM, Bandarenko N, Burchette JL, et al. Tissue transglutaminase expression in human breast cancer. Lab Invest 1996; 75:637–645.
Iacobuzio-Donahue CA, Ashfaq R, Maitra A, et al. Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res 2003; 63:8614–8622.
Mehta K, Fok J, Miller FR, Koul D, Sahin AA. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res 2004; 10:8068–8076.
Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161–1169.
Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55–60.
Papapetropoulos A, Garcia-Cardena G, Dengler TJ, Maisonpierre PC, Yancopoulos GD, Sessa WC. Direct actions of angiopoietin-1 on human endothelium: evidence for network stabilization, cell survival, and interaction with other angiogenic growth factors. Lab Invest 1999; 79:213–223.
Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6:460–463.
Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002; 160:985–1000.
Enholm B, Paavonen K, Ristimaki A, et al. Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRN A regulation by serum, growth factors, oncoproteins and hypoxia. Oncogene 1997; 14:2475–2483.
Mandriota SJ, Pepper MS. Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia. Circ Res 1998; 83:852–859.
Oh H, Takagi H, Suzuma K, Otani A, Matsumura M, Honda Y. Hypoxia and vascular endothelial growth factor selectively up-regulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 1999; 274:15,732–15,739.
Zakrzewicz A, Secomb TW, Pries AR. Angioadaptation: keeping the vascular system in shape. News Physiol Sci 2002; 17:197–201.
Tong S, Yuan F. Numerical simulations of angiogenesis in the cornea. MicrovascRes 2001; 61:14–27.
Li CY, Shan S, Cao Y, Dewhirst MW. Role of incipient angiogenesis in cancer metastasis. Cancer Metastasis Rev 2000; 19:7–11.
Shan S, Robson ND, Cao Y, et al. Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival. FASEB J 2004; 18:326–328.
Krishnamachary B, Berg-Dixon S, Kelly B, et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63:1138–1143.
Wong CW, Song C, Grimes MM, et al. Intravascular location of breast cancer cells after spontaneous metastasis to the lung. Am J Pathol 2002; 161:749–753.
Al-Mehdi AB, Tozawa K, Fisher AB, Shientag L, Lee A, Muschel RJ. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000; 6:100–102.
Burri PH, Djonov, V. Intussusceptive angiogenesis-the alternative to capillary sprouting. Mol Aspects Med 2002; 23(Suppl):S1–S27.
Djonov V, Andres AC, Ziemiecki A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc Res Tech 2001; 52:182–189.
Djonov VG, Kurz H, Burri PH. Optimality in the developing vascular system: branching remodeling by means of intussusception as an efficient adaptation mechanism. Dev Dyn 2002; 224:391–402.
Djonov V, Baum O, Burri PH. Vascular remodeling by intussusceptive angiogenesis. Cell Tissue Res 2003; 314:107–117.
Pries AR, Reglin B, Secomb TW.Structural response of microcirculatory networks to changes in demand: information transfer by shear stress. Am J Physiol 2003; 284:H2204–2212.
Dewhirst MW, Ong ET, Klitzman B, et al. Perivascular oxygen tensions in a transplantable mammary tumor growing in a dorsal flap window chamber. Radiat Res 1992; 130:171–182.
Helmlinger G, Yuan F, Dellian M, Jain RK. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997; 3:177–182.
Dewhirst MW, Ong ET, Braun RD, et al. Quantification of longitudinal tissue pO2 gradients in window chamber tumours: impact on tumour hypoxia. Br J Cancer 1999; 79:1717–1722.
Secomb TW, Hsu R, Braun RD, Ross JR, Gross JF, Dewhirst MW. Theoretical simulation of oxygen transport to tumors by three-dimensional networks of microvessels. Adv Exp Med Biol 1998; 454:629–634.
Dewhirst MW, Secomb TW, Ong ET, Hsu R, Gross JF. Determination of local oxygen consumption rates in tumors. Cancer Res 1994; 54:3333–3336.
Kavanagh BD, Coffey BE, Needham D, Hochmuth RM, Dewhirst MW The effect of flunarizine on erythrocyte suspension viscosity under conditions of extreme hypoxia, low pH, and lactate treatment. Br J Cancer 1993; 67:734–741.
Haroon ZA, Raleigh JA, Greenberg CS, Dewhirst MW. Early wound healing exhibits cytokine surge without evidence of hypoxia. Ann Surg 2000; 231:137–147.
Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996; 379:88–91.
Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315:1650–1659.
Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992; 52:6702–6704.
Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to therapy. Int J Cancer 1995; 61:732–737.
Denekamp J. Review article: Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993; 66:181–196.
Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumorresponse to radiotherapy regulated by endothelial cell apoptosis. Science 2003; 300:1155–1159.
Brown M, Bristow R, Glazer P, et al. Comment on "e;Tumor response to radiotherapy regulated by endothelial cell apoptosis"e; (II). Science 2003; 302:1894; author reply 1894.
Rubin P, Casarett G. Microcirculation of tumors. II. The supervascularized state of irradiated regressing tumors. Clin Radiol 1966; 17:346–355.
Hilmas DE, Gillette EL. Tumormicrovasculature following fractionated X-irradiation. Radiology 1975; 116:165–169.
Dewhirst MW, Oliver R, Tso CY, Gustafson C, Secomb T, Gross JF. Heterogeneity in tumor micro vascular response to radiation. Int J Radiat Oncol Biol Phys 1990; 18:559–568.
Moeller BJ, Cao Y, Li CY, Dewhirst MW. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 2004; 5:429–41.
Gilks N, Kedersha N, Ayodele M, et al. Stress granule assembly is mediated by prion-like aggregation of TIA-1. Mol Biol Cell 2004; 15:5383–5398.
Kedersha N, Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 2002; 30(Pt 6):963–969.
Milas L, Hunter N, Mason KA, Milross C, Peters LJ. Tumor reoxygenation as a mechanism of taxolinduced enhancement of tumor radioresponse. Acta Oncol 1995; 34(3):409–412.
Vujaskovic Z, Song CW. Physiological mechanisms underlying heat-induced radiosensitization. Int J Hyperthermia 2004; 20:163–174.
Jones EL, Prosnitz LR, Dewhirst MW, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004; 10:4287–1293.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Dewhirst, M.W., Cao, Y., Moeller, B., Li, CY. (2006). The Cycle Between Angiogenesis, Perfusion, and Hypoxia in Tumors. In: Teicher, B.A. (eds) Cancer Drug Resistance. Cancer Drug Discovery and Development. Humana Press. https://doi.org/10.1007/978-1-59745-035-5_1
Download citation
DOI: https://doi.org/10.1007/978-1-59745-035-5_1
Publisher Name: Humana Press
Print ISBN: 978-1-58829-530-9
Online ISBN: 978-1-59745-035-5
eBook Packages: MedicineMedicine (R0)